Overview

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety, tolerability and efficacy of milnacipran in patients with an inadequate response to duloxetine for the treatment of fibromyalgia.
Phase:
Phase 4
Details
Lead Sponsor:
Forest Laboratories
Collaborator:
Cypress Bioscience, Inc.
Treatments:
Duloxetine Hydrochloride
Levomilnacipran
Milnacipran